2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10585A
    Valproic acid sodium 1069-66-5 ≥99.0%
    Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid sodium
  • HY-13771
    Ursodeoxycholic acid 128-13-2 ≥98.0%
    Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
    Ursodeoxycholic acid
  • HY-44134
    Dimethyl 2-oxoglutarate 13192-04-6
    Dimethyl 2-oxoglutarate (Dimethyl α-ketoglutarate), a cell permeable 2-oxoglutarate derivative, is a tricarboxylic acid cycle metabolite with antioxidant properties. Dimethyl 2-oxoglutarate serves as a crucial intermediate in the Krebs cycle and an essential nitrogen carrier in metabolic pathways during biological processes. Dimethyl 2-oxoglutarate inhibits autophagy in an IDH1-, IDH2- and ACLY-dependent fashion in cultured human cells. Dimethyl 2-oxoglutarate efficiently prevents autophagy induced by starvation in mice.
    Dimethyl 2-oxoglutarate
  • HY-P0264
    Exendin(9-39) amide 133514-43-9 99.81%
    Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH).
    Exendin(9-39) amide
  • HY-101193
    Zinc Protoporphyrin 15442-64-5 ≥98.0%
    Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) is an orally active and competitive heme oxygenase-1 (HO-1) inhibitor. Zinc Protoporphyrin regulates expression of HO-1 at the transcriptional level. The effect of Zinc Protoporphyrin on HO-1 expression is controversial.  It was shown to induce HO-1 expression in some cells, but suppress it in others. Zinc Protoporphyrin is used as a screening marker of iron deficiency in vivo. Zinc Protoporphyrin has anti-cancer activity.
    Zinc Protoporphyrin
  • HY-16995
    Pirinixic acid 50892-23-4 98.81%
    Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
    Pirinixic acid
  • HY-B1511
    Cyclic AMP 60-92-4 ≥98.0%
    Cyclic AMP (Cyclic adenosine monophosphate), adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP is an important second messenger in many biological processes.
    Cyclic AMP
  • HY-15398
    Vitamin D3 67-97-0 ≥98.0%
    Vitamin D3 (Cholecalciferol; Colecalciferol) is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.
    Vitamin D3
  • HY-N0324
    Cholic acid 81-25-4 99.55%
    Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active.
    Cholic acid
  • HY-100564A
    2',3'-cGAMP sodium 2734858-36-5 ≥99.0%
    2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
    2',3'-cGAMP sodium
  • HY-10626
    T0901317 293754-55-9 99.93%
    T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317
  • HY-50202A
    Etomoxir sodium salt 828934-41-4 99.62%
    Etomoxir((R)-(+)-Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
    Etomoxir sodium salt
  • HY-118297
    Ac4ManNAz (80% α isomer) 361154-30-5 ≥98.0%
    Ac4ManNAz is an azido-containing metabolic glycoprotein labeling reagent. Ac4ManNAz can be used to selectively modify proteins. Ac4ManNAz can be used in cell labeling, tracking and proteomic analysis. Ac4ManNAz is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Ac4ManNAz (80% α isomer)
  • HY-13777
    Zoledronic Acid 118072-93-8 99.91%
    Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects.
    Zoledronic Acid
  • HY-17504
    Rosuvastatin Calcium 147098-20-2 99.77%
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin Calcium
  • HY-A0181
    Adenosine monophosphate 61-19-8 ≥98.0%
    Adenosine monophosphate is an adenosine A1 receptor agonist. Adenosine monophosphate has significant antiviral activity against HSV-1 and HSV-2. Adenosine monophosphate is a key cellular metabolite regulating energy homeostasis and signal transduction.
    Adenosine monophosphate
  • HY-18569
    3-Indoleacetic acid 87-51-4 99.94%
    3-Indoleacetic acid is is an IAA hormone and growth regulator that can promote plant nutritional growth through processes such as cell expansion, differentiation, morphogenesis, and organogenesis.
    3-Indoleacetic acid
  • HY-50662
    A-769662 844499-71-4
    A-769662 is a AMP-activated protein kinase (AMPK) activator. A-769662 inhibits the function of the 26S proteasome by an AMPK-independent mechanism and leads to cell cycle arrest. A-769662 directly stimulates partially purified rat liver AMPK (EC50 = 0.8 μM) and inhibits fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 μM). A-769662 can alleviate the symptoms of metabolic diseases such as type 2 diabetes.
    A-769662
  • HY-17538
    ZLN005 49671-76-3 99.92%
    ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).
    ZLN005
  • HY-50108
    GW 4064 278779-30-9 99.79%
    GW 4064 is a potent FXR agonist with an EC50 of 65 nM.
    GW 4064
Cat. No. Product Name / Synonyms Application Reactivity